IP Library Granted Patent US 9,387,253
Granted Patent B2
US 9,387,253 · App. 14/934,425 · Granted Jul 12, 2016

Methods and compositions for wound treatment

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,387,253
App. No.
14/934,425
Granted
Jul 12, 2016
Kind
B2
Abstract

The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.

Claims (21)

1. A composition for treatment of a wound in a subject comprising:

a carrier,

a hemostatic agent and

a wound targeting moiety comprising an antibody specific for actin, wherein the carrier contains the hemostatic agent and is conjugated to the antibody and, further wherein the wound targeting moiety facilitates local delivery of the hemostatic agent to wounded tissue by binding to an actin protein exposed upon wounding of the subject.

2. The composition of claim 1 , wherein the hemostatic agent is a self-assembling peptide.

3. The composition of claim 2 , wherein the self-assembling peptide creates a hydrogel.

4. The composition of claim 3 , wherein the self-assembling peptide is AMAX3-WW.

5. The composition of claim 1 , wherein the carrier is a liposome.

6. A composition for treatment of a wound in a subject comprising:

a carrier,

a hemostatic agent, and

a wound targeting moiety comprising an antibody specific to a cryptic tripeptide arginine-glycine-aspartic acid (RGD) epitope, wherein the carrier contains the hemostatic agent and is conjugated to the antibody, and wherein the antibody facilitates local delivery of the hemostatic agent to wound tissue by binding to an exposed cryptic tripeptide arginine-glycine-aspartic acid (RGD) epitope exposed upon wounding of the subject.

7. The composition of claim 6 , wherein the hemostatic agent is a self-assembling peptide.

8. The composition of claim 7 , wherein the self-assembling peptide creates a hydrogel.

9. The composition of claim 8 , wherein the self-assembling peptide is AMAX3-WW.

10. The composition of claim 6 , wherein the carrier is a liposome.

11. A composition for treatment of a wound in a subject comprising:

a carrier,

an anticoagulant and

a wound targeting moiety comprising an antibody specific for actin, wherein the carrier contains the anticoagulant and is conjugated to the antibody and, further wherein the wound targeting moiety facilitates local delivery of the anticoagulant agent to wounded tissue by binding to an actin protein exposed upon wounding of the subject.

12. The composition of claim 11 , wherein the anticoagulant is an anti-platelet agent.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Jan 17, 2020
From: CITIBANK, N.A., AS COLLATERAL AGENT
To: LEIDOS, INC.
Reel/Frame 051632/0819 →
RELEASE OF SECURITY INTEREST Recorded Jan 17, 2020
From: CITIBANK, N.A., AS COLLATERAL AGENT
To: LEIDOS, INC.
Reel/Frame 051632/0742 →
SECURITY INTEREST Recorded Aug 25, 2016
From: LEIDOS, INC.
To: CITIBANK, N.A.
Reel/Frame 039809/0801 →
SECURITY INTEREST Recorded Aug 25, 2016
From: LEIDOS, INC.
To: CITIBANK, N.A.
Reel/Frame 039818/0272 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2015
From: GRIFFEY, RICHARD HOLMES
To: SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
Reel/Frame 036978/0341 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2015
From: DRESIOS, JOHN
To: SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
Reel/Frame 036978/0280 →
CHANGE OF NAME Recorded Nov 6, 2015
From: SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
To: LEIDOS, INC.
Reel/Frame 037065/0736 →